CytoMed Therapeutics Ltd
Company Profile
Business description
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Contact
1 Commonwealth Lane
No. 08-22 One Commonwealth
Singapore149544
SGPT: +65 62507738
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
42
Stocks News & Analysis
stocks
ASX giant falls short on copper guidance
stocks
Pure-play data center share raises capital to fund AI demand
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,974.70 | 32.40 | -0.36% |
| CAC 40 | 8,332.11 | 6.70 | -0.08% |
| DAX 40 | 24,776.48 | 54.50 | -0.22% |
| Dow JONES (US) | 52,043.23 | 103.19 | -0.20% |
| FTSE 100 | 10,520.79 | 79.58 | -0.75% |
| HKSE | 25,143.05 | 580.81 | 2.36% |
| NASDAQ | 25,664.23 | 143.99 | 0.56% |
| Nikkei 225 | 64,141.12 | 2,694.42 | -4.03% |
| NZX 50 Index | 13,696.03 | 1.35 | 0.01% |
| S&P 500 | 7,478.32 | 20.63 | 0.28% |
| S&P/ASX 200 | 8,791.30 | 31.00 | -0.35% |
| SSE Composite Index | 3,796.28 | 32.13 | 0.85% |